{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:13Z","timestamp":1789104673743,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cct.2021.106674","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T18:39:34Z","timestamp":1641235174000},"page":"106674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale"],"prefix":"10.1016","volume":"114","author":[{"given":"Andres","family":"Perez-Correa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Riback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ghiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinazo O.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106674_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2021.106674_bb0010","series-title":"NAM Perspectives. Discussion Paper, Washington, DC","author":"Madras","year":"2020"},{"key":"10.1016\/j.cct.2021.106674_bb0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths - United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.cct.2021.106674_bb0020","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2021.106674_bb0025","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0030","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2021.106674_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","article-title":"Description and outcomes of a buprenorphine maintenance treatment program integrated within prevention point Philadelphia, an urban syringe exchange program","volume":"39","author":"Bachhuber","year":"2018","journal-title":"Subst. Abus."},{"key":"10.1016\/j.cct.2021.106674_bb0045","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jama.2021.1741","article-title":"Overcoming barriers to treatment of opioid use disorder","volume":"325","author":"Olsen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2021.106674_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2021.106674_bb0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jsat.2013.09.003","article-title":"Determinants of buprenorphine treatment for opioid dependence","volume":"46","author":"Murphy","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsat.2011.02.002","article-title":"Factors associated with Medicaid patients\u2019 access to buprenorphine treatment","volume":"41","author":"Baxter","year":"2011","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in new York City","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"10.1016\/j.cct.2021.106674_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/003335490411900109","article-title":"An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models","volume":"119","author":"Heller","year":"2004","journal-title":"Public Health Rep."},{"key":"10.1016\/j.cct.2021.106674_bb0075","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1360-0443.2008.02465.x","article-title":"Doing harm reduction better: syringe exchange in the United States","volume":"104","author":"Des Jarlais","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2021.106674_bb0080","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm6448a3","article-title":"Syringe service programs for persons who inject drugs in urban, suburban, and rural areas - United States, 2013","volume":"64","author":"Des Jarlais","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.cct.2021.106674_bb0085","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1081\/JA-120014088","article-title":"Drug user treatment referrals and entry among participants of a needle exchange program","volume":"37","author":"Riley","year":"2002","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.cct.2021.106674_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12954-017-0149-y","article-title":"Development and evaluation of a community-based buprenorphine treatment intervention","volume":"14","author":"Fox","year":"2017","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.cct.2021.106674_bb0095","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jurban\/jti091","article-title":"Challenges in motivating treatment enrollment in community syringe exchange participants","volume":"82","author":"Kidorf","year":"2005","journal-title":"J. Urban Health"},{"key":"10.1016\/j.cct.2021.106674_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08897077.2015.1011820","article-title":"Harm reduction agencies as a potential site for buprenorphine treatment","volume":"36","author":"Fox","year":"2015","journal-title":"Subst. Abus."},{"issue":"2","key":"10.1016\/j.cct.2021.106674_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med."},{"key":"10.1016\/j.cct.2021.106674_bb0110","article-title":"Low-threshold buprenorphine treatment in a syringe services program: program description and outcomes","author":"Jakubowski","year":"2021","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0115","first-page":"1","article-title":"\u201cWe\u2019ll be able to take care of ourselves\u201d - a qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs","author":"Frost","year":"2021","journal-title":"Subst. Abus."},{"key":"10.1016\/j.cct.2021.106674_bb0120","first-page":"1","article-title":"Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington","author":"Hood","year":"2019","journal-title":"Subst. Abus."},{"key":"10.1016\/j.cct.2021.106674_bb0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/10550887.2012.694603","article-title":"Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations","volume":"31","author":"Stancliff","year":"2012","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2021.106674_bb0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.cct.2021.106674_bb0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2021.106674_bb0140","series-title":"North American Syringe Exchange Network","author":"NASEN","year":"2021"},{"key":"10.1016\/j.cct.2021.106674_bb0145","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1353\/hpu.0.0051","article-title":"Delivering care out of the box: the evolution of an HIV harm reduction medical program","volume":"19","author":"Mund","year":"2008","journal-title":"J. Health Care Poor Underserved"},{"issue":"Suppl. 20","key":"10.1016\/j.cct.2021.106674_bb0150","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2021.106674_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.cct.2021.106674_bb0160","series-title":"Encylopedia of Health Economics","first-page":"341","article-title":"Multiattribute utility instruments and their use","author":"Richardson","year":"2014"},{"key":"10.1016\/j.cct.2021.106674_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0170","series-title":"Comparison of self-report and official data for measuring crime. Measurement problems in criminal justice research: Workshop summary","first-page":"43","author":"Thornberry","year":"2003"},{"key":"10.1016\/j.cct.2021.106674_bb0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1300\/J076v30n03_07","article-title":"The validity of self-reported criminal arrest history among clients of a psychiatric probation and parole service","volume":"30","author":"Nieves","year":"2000","journal-title":"J. Offender Rehabil."},{"key":"10.1016\/j.cct.2021.106674_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-8-2","article-title":"Validity of self-reported criminal justice system involvement in substance abusing women at five-year follow-up","volume":"8","author":"Jansson","year":"2008","journal-title":"BMC psychiatry"},{"issue":"161","key":"10.1016\/j.cct.2021.106674_bb0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2016.01.021","article-title":"Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial","volume":"1","author":"Murphy","year":"2016","journal-title":"Drug Alcohol Depen"},{"key":"10.1016\/j.cct.2021.106674_bb0190","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal-justice-involved persons with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2021.106674_bb0195","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","article-title":"Cost-effectiveness of extended buprenorphine\u2013naloxone treatment for opioid-dependent youth: data from a randomized trial","volume":"105","author":"Polsky","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2021.106674_bb0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40352-018-0073-6","article-title":"Criminal justice measures for economic data harmonization in substance use disorder research","volume":"6","author":"McCollister","year":"2018","journal-title":"Health & justice"},{"key":"10.1016\/j.cct.2021.106674_bb0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13011-017-0107-4","article-title":"Cohort profile: seek, test, treat and retain United States criminal justice cohort","volume":"12","author":"Chandler","year":"2017","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"10.1016\/j.cct.2021.106674_bb0215","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11606-006-0050-y","article-title":"Patient satisfaction with primary care office-based buprenorphine\/naloxone treatment","volume":"22","author":"Barry","year":"2007","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1037\/0893-164X.10.2.81","article-title":"Assessing drinkers\u2019 motivation for change: the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)","volume":"10","author":"Miller","year":"1996","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.cct.2021.106674_bb0225","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/01.chi.0000199027.68828.b3","article-title":"Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications","volume":"45","author":"Wilens","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.cct.2021.106674_bb0230","first-page":"1273","article-title":"The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people","volume":"34","author":"Gelberg","year":"2000","journal-title":"Health Serv. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.cct.2021.106674_bb0235","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/508183","article-title":"Initial strategies for integrating buprenorphine into HIV care settings in the United States","volume":"43","author":"Sullivan","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2021.106674_bb0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","article-title":"A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions","volume":"40","author":"Cunningham","year":"2011","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0245","first-page":"500","article-title":"Buprenorphine treatment in an urban community health center: what to expect","volume":"40","author":"Cunningham","year":"2008","journal-title":"Fam. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0250","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial","volume":"66","author":"Woody","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cct.2021.106674_bb0255","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.cct.2021.106674_bb0260","series-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.cct.2021.106674_bb0265","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.cct.2021.106674_bb0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ADM.0000000000000096","article-title":"The stepped treatment engagement protocol for homeless, needle exchange heroin-dependent patients","volume":"9","author":"Tringale","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ADM.0000000000000004","article-title":"A novel community-based buprenorphine program: client description and initial outcomes","volume":"8","author":"Daniels","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2021.106674_bb0280","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1360-0443.2009.02560.x","article-title":"Improving substance abuse treatment enrollment in community syringe exchangers","volume":"104","author":"Kidorf","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2021.106674_bb0285","doi-asserted-by":"crossref","first-page":"107537","DOI":"10.1016\/j.drugalcdep.2019.06.039","article-title":"Touchpoints - opportunities to predict and prevent opioid overdose: a cohort study","volume":"204","author":"Larochelle","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2021.106674_bb0290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.drugpo.2016.09.003","article-title":"Rethinking retention in treatment of opioid dependence-the eye of the beholder","volume":"39","author":"Vogel","year":"2017","journal-title":"Int J Drug Policy."},{"key":"10.1016\/j.cct.2021.106674_bb0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"issue":"4","key":"10.1016\/j.cct.2021.106674_bb0300","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year","volume":"37","author":"Soeffing","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat."},{"key":"10.1016\/j.cct.2021.106674_bb0310","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1360-0443.1999.94572310.x","article-title":"A brief measure for the assessment of coping self-efficacy among alcohol and other drug users","volume":"94","author":"Sklar","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2021.106674_bb0315","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self-report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl. Psychol. Meas."},{"key":"10.1016\/j.cct.2021.106674_bb0320","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","article-title":"Stigma, discrimination and the health of illicit drug users","volume":"88","author":"Ahern","year":"2007","journal-title":"Drug Alcohol Depend."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:54:28Z","timestamp":1761555268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":64,"alternative-id":["S1551714421004109"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106674","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106674"}}